Report cover image

Global Complement Targeted Therapeutics Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 194 Pages
SKU # APRC20561578

Description

Summary

According to APO Research, The global Complement Targeted Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Complement Targeted Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Complement Targeted Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Complement Targeted Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Complement Targeted Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Complement Targeted Therapeutics include Alexion Pharmaceuticals, Allergan, Creative Biolabs, AbbVie, Pfizer, Merck and Novartis AG, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Complement Targeted Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Complement Targeted Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Complement Targeted Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Complement Targeted Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Complement Targeted Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Complement Targeted Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Complement Targeted Therapeutics Segment by Company

Alexion Pharmaceuticals
Allergan
Creative Biolabs
AbbVie
Pfizer
Merck
Novartis AG
Complement Targeted Therapeutics Segment by Type

Paroxysmal Nocturnal Haemoglobinuria
Atypical Haemolytic Uraemic Syndrome (AHUS)
Complement Targeted Therapeutics Segment by Application

Retail Pharamacies
Online Pharmacies
Hospital Pharmacies
Complement Targeted Therapeutics Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Complement Targeted Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Complement Targeted Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Complement Targeted Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Complement Targeted Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Complement Targeted Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Complement Targeted Therapeutics revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Complement Targeted Therapeutics Market by Type
1.2.1 Global Complement Targeted Therapeutics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Paroxysmal Nocturnal Haemoglobinuria
1.2.3 Atypical Haemolytic Uraemic Syndrome (AHUS)
1.3 Complement Targeted Therapeutics Market by Application
1.3.1 Global Complement Targeted Therapeutics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Retail Pharamacies
1.3.3 Online Pharmacies
1.3.4 Hospital Pharmacies
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Complement Targeted Therapeutics Market Dynamics
2.1 Complement Targeted Therapeutics Industry Trends
2.2 Complement Targeted Therapeutics Industry Drivers
2.3 Complement Targeted Therapeutics Industry Opportunities and Challenges
2.4 Complement Targeted Therapeutics Industry Restraints
3 Global Growth Perspective
3.1 Global Complement Targeted Therapeutics Market Perspective (2020-2031)
3.2 Global Complement Targeted Therapeutics Growth Trends by Region
3.2.1 Global Complement Targeted Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Complement Targeted Therapeutics Market Size by Region (2020-2025)
3.2.3 Global Complement Targeted Therapeutics Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Complement Targeted Therapeutics Revenue by Players
4.1.1 Global Complement Targeted Therapeutics Revenue by Players (2020-2025)
4.1.2 Global Complement Targeted Therapeutics Revenue Market Share by Players (2020-2025)
4.1.3 Global Complement Targeted Therapeutics Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Complement Targeted Therapeutics Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Complement Targeted Therapeutics Key Players Headquarters & Area Served
4.4 Global Complement Targeted Therapeutics Players, Product Type & Application
4.5 Global Complement Targeted Therapeutics Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Complement Targeted Therapeutics Market CR5 and HHI
4.6.3 2024 Complement Targeted Therapeutics Tier 1, Tier 2, and Tier 3
5 Complement Targeted Therapeutics Market Size by Type
5.1 Global Complement Targeted Therapeutics Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Complement Targeted Therapeutics Revenue by Type (2020-2031)
5.3 Global Complement Targeted Therapeutics Revenue Market Share by Type (2020-2031)
6 Complement Targeted Therapeutics Market Size by Application
6.1 Global Complement Targeted Therapeutics Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Complement Targeted Therapeutics Revenue by Application (2020-2031)
6.3 Global Complement Targeted Therapeutics Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Alexion Pharmaceuticals
7.1.1 Alexion Pharmaceuticals Comapny Information
7.1.2 Alexion Pharmaceuticals Business Overview
7.1.3 Alexion Pharmaceuticals Complement Targeted Therapeutics Revenue and Gross Margin (2020-2025)
7.1.4 Alexion Pharmaceuticals Complement Targeted Therapeutics Product Portfolio
7.1.5 Alexion Pharmaceuticals Recent Developments
7.2 Allergan
7.2.1 Allergan Comapny Information
7.2.2 Allergan Business Overview
7.2.3 Allergan Complement Targeted Therapeutics Revenue and Gross Margin (2020-2025)
7.2.4 Allergan Complement Targeted Therapeutics Product Portfolio
7.2.5 Allergan Recent Developments
7.3 Creative Biolabs
7.3.1 Creative Biolabs Comapny Information
7.3.2 Creative Biolabs Business Overview
7.3.3 Creative Biolabs Complement Targeted Therapeutics Revenue and Gross Margin (2020-2025)
7.3.4 Creative Biolabs Complement Targeted Therapeutics Product Portfolio
7.3.5 Creative Biolabs Recent Developments
7.4 AbbVie
7.4.1 AbbVie Comapny Information
7.4.2 AbbVie Business Overview
7.4.3 AbbVie Complement Targeted Therapeutics Revenue and Gross Margin (2020-2025)
7.4.4 AbbVie Complement Targeted Therapeutics Product Portfolio
7.4.5 AbbVie Recent Developments
7.5 Pfizer
7.5.1 Pfizer Comapny Information
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Complement Targeted Therapeutics Revenue and Gross Margin (2020-2025)
7.5.4 Pfizer Complement Targeted Therapeutics Product Portfolio
7.5.5 Pfizer Recent Developments
7.6 Merck
7.6.1 Merck Comapny Information
7.6.2 Merck Business Overview
7.6.3 Merck Complement Targeted Therapeutics Revenue and Gross Margin (2020-2025)
7.6.4 Merck Complement Targeted Therapeutics Product Portfolio
7.6.5 Merck Recent Developments
7.7 Novartis AG
7.7.1 Novartis AG Comapny Information
7.7.2 Novartis AG Business Overview
7.7.3 Novartis AG Complement Targeted Therapeutics Revenue and Gross Margin (2020-2025)
7.7.4 Novartis AG Complement Targeted Therapeutics Product Portfolio
7.7.5 Novartis AG Recent Developments
8 North America
8.1 North America Complement Targeted Therapeutics Revenue (2020-2031)
8.2 North America Complement Targeted Therapeutics Revenue by Type (2020-2031)
8.2.1 North America Complement Targeted Therapeutics Revenue by Type (2020-2025)
8.2.2 North America Complement Targeted Therapeutics Revenue by Type (2026-2031)
8.3 North America Complement Targeted Therapeutics Revenue Share by Type (2020-2031)
8.4 North America Complement Targeted Therapeutics Revenue by Application (2020-2031)
8.4.1 North America Complement Targeted Therapeutics Revenue by Application (2020-2025)
8.4.2 North America Complement Targeted Therapeutics Revenue by Application (2026-2031)
8.5 North America Complement Targeted Therapeutics Revenue Share by Application (2020-2031)
8.6 North America Complement Targeted Therapeutics Revenue by Country
8.6.1 North America Complement Targeted Therapeutics Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Complement Targeted Therapeutics Revenue by Country (2020-2025)
8.6.3 North America Complement Targeted Therapeutics Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Complement Targeted Therapeutics Revenue (2020-2031)
9.2 Europe Complement Targeted Therapeutics Revenue by Type (2020-2031)
9.2.1 Europe Complement Targeted Therapeutics Revenue by Type (2020-2025)
9.2.2 Europe Complement Targeted Therapeutics Revenue by Type (2026-2031)
9.3 Europe Complement Targeted Therapeutics Revenue Share by Type (2020-2031)
9.4 Europe Complement Targeted Therapeutics Revenue by Application (2020-2031)
9.4.1 Europe Complement Targeted Therapeutics Revenue by Application (2020-2025)
9.4.2 Europe Complement Targeted Therapeutics Revenue by Application (2026-2031)
9.5 Europe Complement Targeted Therapeutics Revenue Share by Application (2020-2031)
9.6 Europe Complement Targeted Therapeutics Revenue by Country
9.6.1 Europe Complement Targeted Therapeutics Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Complement Targeted Therapeutics Revenue by Country (2020-2025)
9.6.3 Europe Complement Targeted Therapeutics Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Complement Targeted Therapeutics Revenue (2020-2031)
10.2 China Complement Targeted Therapeutics Revenue by Type (2020-2031)
10.2.1 China Complement Targeted Therapeutics Revenue by Type (2020-2025)
10.2.2 China Complement Targeted Therapeutics Revenue by Type (2026-2031)
10.3 China Complement Targeted Therapeutics Revenue Share by Type (2020-2031)
10.4 China Complement Targeted Therapeutics Revenue by Application (2020-2031)
10.4.1 China Complement Targeted Therapeutics Revenue by Application (2020-2025)
10.4.2 China Complement Targeted Therapeutics Revenue by Application (2026-2031)
10.5 China Complement Targeted Therapeutics Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Complement Targeted Therapeutics Revenue (2020-2031)
11.2 Asia Complement Targeted Therapeutics Revenue by Type (2020-2031)
11.2.1 Asia Complement Targeted Therapeutics Revenue by Type (2020-2025)
11.2.2 Asia Complement Targeted Therapeutics Revenue by Type (2026-2031)
11.3 Asia Complement Targeted Therapeutics Revenue Share by Type (2020-2031)
11.4 Asia Complement Targeted Therapeutics Revenue by Application (2020-2031)
11.4.1 Asia Complement Targeted Therapeutics Revenue by Application (2020-2025)
11.4.2 Asia Complement Targeted Therapeutics Revenue by Application (2026-2031)
11.5 Asia Complement Targeted Therapeutics Revenue Share by Application (2020-2031)
11.6 Asia Complement Targeted Therapeutics Revenue by Country
11.6.1 Asia Complement Targeted Therapeutics Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Complement Targeted Therapeutics Revenue by Country (2020-2025)
11.6.3 Asia Complement Targeted Therapeutics Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Complement Targeted Therapeutics Revenue (2020-2031)
12.2 SAMEA Complement Targeted Therapeutics Revenue by Type (2020-2031)
12.2.1 SAMEA Complement Targeted Therapeutics Revenue by Type (2020-2025)
12.2.2 SAMEA Complement Targeted Therapeutics Revenue by Type (2026-2031)
12.3 SAMEA Complement Targeted Therapeutics Revenue Share by Type (2020-2031)
12.4 SAMEA Complement Targeted Therapeutics Revenue by Application (2020-2031)
12.4.1 SAMEA Complement Targeted Therapeutics Revenue by Application (2020-2025)
12.4.2 SAMEA Complement Targeted Therapeutics Revenue by Application (2026-2031)
12.5 SAMEA Complement Targeted Therapeutics Revenue Share by Application (2020-2031)
12.6 SAMEA Complement Targeted Therapeutics Revenue by Country
12.6.1 SAMEA Complement Targeted Therapeutics Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Complement Targeted Therapeutics Revenue by Country (2020-2025)
12.6.3 SAMEA Complement Targeted Therapeutics Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.